The GLP-1 Economy — Digest
TL;DR
The oral market flipped this cycle: Lilly's Foundayo surged 21% to 64K weekly scripts while Novo's Wegovy pill stalled at ~182K for a fifth straight week, and Lilly's share of the oral obesity market hit 26%. Novo's slide deepened — the ADR is down 21.4% in a month, trading at a 9.4 P/E, roughly one-sixth of Lilly's $1.02T market cap. Meanwhile, EASD 2026 made clear the next battleground is amylin combinations, and the ripple effects now have hard numbers attached: Cornell finds grocery spending falls 5–8% after a household adopts a GLP-1.
The Oral Market Flips to Lilly
The oral GLP-1 race just stopped being a launch-curve story and became a share-shift story.
"Novo's Wegovy pill scripts appear stuck at just above $180K"
— Fierce Pharma's Oral GLP-1 Tracker
The specifics: Foundayo posted 64,268 weekly prescriptions, up ~21% sequentially on top of a 13% gain the prior week, while the Wegovy pill has hovered between 181K and 184K for five weeks. Lilly's oral share hit 26%, up from just under 23% two weeks earlier (Oral GLP-1 Tracker). The drivers are identifiable — a Martha Stewart DTC ad, the Medicare Bridge program, and the September 1 starter-dose price cut to $149/$199 — and both CEOs are now making dueling share claims: Ricks says Foundayo captures "about 1 out of 3 new starts for oral GLP-1 obesity drugs," while Novo told Reuters it is "capturing more than 80% of new oral prescriptions" (Reuters via U.S. News). That metric gap itself is the tell: the narrative is contested enough that each side is picking its own denominator.
What to watch: Whether Foundayo's share of the oral market crosses 30% — the thread opened this cycle flags that as the point where the launch narrative flips decisively and pressures Wegovy pill economics ahead of Novo's January 1, 2027 list-price cut.
Novo's Discount Keeps Widening
Last cycle's digest noted Novo got punished for a modest CMD; this cycle shows the punishment compounding rather than mean-reverting.
"Its shares have tumbled more than 70% from their peak, as Lilly has overtaken Novo as the obesity-drug market leader."
— Reuters via U.S. News
At $37.32 (Oct 2 close), NVO is down 21.4% in a month and 38.9% from its 52-week high, with RSI at 21 — deeply oversold — and volume drying up (NVO market view). The cost discipline is visible: 108 job cuts at the Plainsboro, NJ U.S. headquarters effective December 31, part of a broader U.S. sales restructuring, and the FDA extended review of hemophilia drug denecimig over "ongoing remediation work at a manufacturing facility" — the same class of facility issues that has slowed Novo's U.S. capacity ramp (NVO market view). The counter-case is real — Novo claims >80% of new oral prescriptions, the Wegovy pill has launched in four countries, and a 194-patient real-world switch study with telehealth firm Ro showed patients moving from injectables lost an average 4.1% of body weight over three months — but none of it is moving the stock. CagriSema's Q4 2026 FDA decision remains the nearest re-rating catalyst.
What to watch: Q3 earnings in early November — the first hard read on whether the Wegovy pill stall is noise or trend.
Amylin Is the New Efficacy Frontier
EASD 2026 in Milan made the strategic direction obvious: both incumbents are pivoting their next-generation narrative to amylin-based combinations.
"helped people who were overweight or had obesity and also had Type 2 diabetes to lose 23% of their starting body weight compared to 14.8% among those using tirzepatide alone after nearly a year"
— TIME
That's Lilly's EloraTZP (eloralintide + tirzepatide). Novo countered with CagriSema at 22.4% weight loss at one year versus placebo, plus fMRI evidence it blunts "food noise." The mechanism's appeal is tolerability: Dr. Timothy Garvey, who led Zealand/Roche's petrelintide Phase 2 (10% weight loss vs. 1.7% placebo, Phase 3 begun September 22), said "The amylins still cause some nausea, but it's at less than half the rate of what we generally see in GLP-1 trials" (TIME). The challenger wave is broad and increasingly amylin-centric — Pfizer's monthly berobenatide (Metsera), AbbVie's ABBV-295, Roche's enicepatide — and Amgen's MARITIME-SWITCH trial is enrolling patients moving off weekly tirzepatide/semaglutide onto every-8-week or quarterly dosing: "Amgen is, in no uncertain terms, coming after Novo and Eli Lilly's customers" (Barchart).
What to watch: Amgen's MariTide switch-trial data — the first direct test of whether dosing convenience can pull patients off the incumbents' franchises.
Pricing Is Now the Competitive Weapon
The cash-pay market is bifurcating, and $149 has become the marginal clearing price for an oral GLP-1 trial start.
"Wegovy's cash price has dropped 75 percent since 2021 as drugmakers compete directly for patients"
— The Daily Economy
The Medicare GLP-1 Bridge — $50 monthly copays for eligible Part D seniors, live since July 1 — has reached ~700,000 seniors, and Ricks says Lilly is capturing "7 out of 10" Bridge patients (Fierce Pharma tracker). That's the single biggest public-reimbursement opening for obesity drugs to date, and it's Lilly-skewed. Meanwhile, with fewer than one in five large employers covering GLP-1s for obesity and half of Wegovy/Zepbound sales now direct exchanges with cash payers, the U.S. market is splitting into three channels: a shrinking commercial-formulary channel, a fast-growing $50-copay Medicare channel, and a dominant cash/DTC channel where Lilly's $149 starter pricing is the weapon (The Daily Economy).
What to watch: Whether Novo closes the Bridge enrollment gap — the thread tracking Bridge dynamics is the right place to steer that question.
Viking Round-Trips; the Market Still Pays for Mechanism
The maintenance data from last cycle's digest got the full market treatment: spike, then dilution.
"Those taking the medicine every other week maintained up to 97% of their weight loss three months after switching to this new dosing schedule, and patients taking it monthly maintained up to 90%."
— The Motley Fool
VKTX surged 36% on the readout, then closed a $575.0M stock-and-convertible offering on September 28 — necessary given $125.8M cash against $125.2M of quarterly burn as of June 30 — leaving the stock at $29.94 by Oct 2, down 27.2% over three months (VKTX market view). The contrast with Structure Therapeutics is instructive: GPCR is down 41.6% in a month (RSI 16) with no single confirmed catalyst — an EPS miss, a year-long grind, and compression of the oral GLP-1 premium thesis as Foundayo scales at $149. Differentiated mechanism gets rewarded; undifferentiated oral exposure doesn't.
What to watch: The oral VK2735 Phase 3 initiation by year-end, and the Q4 SWITCH readouts that could explain GPCR's slide.
Big Food's Headwind Gets Household-Level Proof
The ripple effects moved from brand-value estimates to measured household behavior.
"grocery spending fell about 5% within six months of a household adopting a GLP-1, and that increased to more than 8% for higher-income households"
— Cornell study via Barchart
Confectionery, chocolate, and savory snacks are the flagged risk categories, with PepsiCo called the weakest of the big three — North American snack volumes and pricing both under pressure, plus an activist investor — while Mondelez has held up best on emerging-market exposure (Barchart). The adoption math behind the pressure: JPMorgan estimates ~10 million Americans were on GLP-1s in 2025, reaching 25–30 million by 2030, and Morgan Stanley projects $190B in global diabetes-plus-obesity drug sales by 2035 versus ~$79B in 2025. The medtech angle sharpened too: Lilly's retatrutide hit 28.3% average weight loss at 80 weeks — against the 25–35% typical of bariatric surgery.
What to watch: Q3/Q4 food-major earnings calls beginning to quantify GLP-1 commentary the way bariatric-surgery volumes already have.
What surprised us
- Novo's switch study is a better defense than its share claims. The 194-patient Ro study — patients losing 4.1% more weight after switching off injectables, obesity prevalence falling from 87.1% to 65.5% — is the first data that makes the Wegovy pill's convenience pitch empirical rather than aspirational (Reuters via U.S. News). It hasn't moved the stock, but it's the argument Novo will lead with.
- Lilly is fighting with cross-trial math now. Pooling ACHIEVE-3 against Novo's PIONEER PLUS and SURMOUNT-1 against STEP UP to claim 1.5–4.5% greater weight loss is commercially useful and scientifically soft — BMO's "indirect but encouraging" framing is generous (BioSpace). Expect Novo to return the favor.
- China is now exporting molecules, not just patients. Novo licensed Hengrui's HRS-1596 pre-Phase 1 for $300M upfront (up to $2.6B), and Pfizer paid up to $495M for China rights to Sciwind's ecnoglutide (Barchart). The licensing geography has flipped.
Open threads worth a vote
The GLP-1 Economy — Digest (Δ for returning readers)
Since last time
- Promoted: Amylin combinations — absent from the last briefing entirely, now a core section after EASD 2026. This is the cycle's biggest new thread.
- Escalated: The oral market story flipped from launch-curve to share-shift (Lilly at 26% oral share); Novo's discount went from one bad CMD to compounding decline (-21.4% in a month, 70%+ off peak); pricing graduated from a $149 starter-price footnote to a full channel-bifurcation section; Viking moved from "bullish readout" to "round-trip complete" with financing and a Structure Therapeutics contrast; Big Food moved from brand-value estimates to measured household-level data.
- Demoted: CagriSema's head-to-head win — a full section last cycle, now only passing mentions (the Q4 2026 FDA decision as Novo's re-rating catalyst, and CagriSema's 22.4% figure inside the amylin section). The CMD specifics (targets, Doustdar quote, launch calendar) are compressed to a one-line callback.
- Disappeared: The NAION litigation overhang (MDL-3163, the EU/US label gap, Weitz & Luxembourg suits) — entirely absent from this briefing, not even a passing mention. Also gone: the Citi 12-point script-growth swing datapoint behind last cycle's "orals are recruiting, not cannibalizing" claim.
- Unchanged: Nothing qualifies — every section carries new substance this cycle.
The Oral Market Flips to Lilly (Escalated)
Last cycle this was a launch-curve story with both pills setting records; this cycle it's share-shift, and Lilly is winning it.
"Novo's Wegovy pill scripts appear stuck at just above $180K"
— Fierce Pharma's Oral GLP-1 Tracker
Foundayo posted 64,268 weekly scripts, up ~21% sequentially on top of the prior week's 13% gain, while the Wegovy pill has hovered between 181K and 184K for five weeks. Lilly's oral share hit 26%, up from just under 23% two weeks earlier (Oral GLP-1 Tracker). Drivers: a Martha Stewart DTC ad, the Medicare Bridge program, and the September 1 starter-dose cut to $149/$199. Both CEOs now make dueling share claims — Ricks says Foundayo captures "about 1 out of 3 new starts for oral GLP-1 obesity drugs," while Novo told Reuters it is "capturing more than 80% of new oral prescriptions" (Reuters via U.S. News). The metric gap is itself the tell: each side is picking its own denominator.
What to watch: Whether Foundayo's share crosses 30% — the new thread flags that as the point where the launch narrative flips decisively and pressures Wegovy pill economics ahead of Novo's January 1, 2027 list-price cut.
Novo's Discount Keeps Widening (Escalated, with CMD details demoted)
Last cycle's CMD modesty story has become a compounding decline rather than a mean-reversion setup.
"Its shares have tumbled more than 70% from their peak, as Lilly has overtaken Novo as the obesity-drug market leader."
— Reuters via U.S. News
NVO at $37.32 (Oct 2 close) is down 21.4% in a month and 38.9% from its 52-week high, RSI at 21, volume drying up (NVO market view). New cost-discipline signals: 108 job cuts at the Plainsboro, NJ U.S. headquarters effective December 31, and the FDA extended review of hemophilia drug denecimig over "ongoing remediation work at a manufacturing facility" — the same class of facility issues slowing Novo's U.S. capacity ramp (NVO market view). The counter-case: Novo's >80% new-oral-prescriptions claim, launches in four countries, and a 194-patient real-world Ro switch study showing patients moving off injectables lost an average 4.1% of body weight over three months — none of it moving the stock. CagriSema's Q4 2026 FDA decision remains the nearest re-rating catalyst (the head-to-head section from last cycle is now folded into this single line).
What to watch: Q3 earnings in early November — the first hard read on whether the Wegovy pill stall is noise or trend.
Amylin Is the New Efficacy Frontier (Promoted — new this cycle)
EASD 2026 in Milan made the strategic direction obvious: both incumbents are pivoting their next-generation narrative to amylin-based combinations.
"helped people who were overweight or had obesity and also had Type 2 diabetes to lose 23% of their starting body weight compared to 14.8% among those using tirzepatide alone after nearly a year"
— TIME
That's Lilly's EloraTZP (eloralintide + tirzepatide). Novo countered with CagriSema at 22.4% weight loss at one year versus placebo, plus fMRI evidence it blunts "food noise." The mechanism's appeal is tolerability: Dr. Timothy Garvey, who led Zealand/Roche's petrelintide Phase 2 (10% weight loss vs. 1.7% placebo, Phase 3 begun September 22), said "The amylins still cause some nausea, but it's at less than half the rate of what we generally see in GLP-1 trials" (TIME). The challenger wave is broad and increasingly amylin-centric — Pfizer's monthly berobenatide (Metsera), AbbVie's ABBV-295, Roche's enicepatide — and Amgen's MARITIME-SWITCH trial is enrolling patients moving off weekly tirzepatide/semaglutide onto every-8-week or quarterly dosing: "Amgen is, in no uncertain terms, coming after Novo and Eli Lilly's customers" (Barchart).
What to watch: Amgen's MariTide switch-trial data — the first direct test of whether dosing convenience can pull patients off the incumbents' franchises.
Pricing Is Now the Competitive Weapon (Escalated)
Last cycle's $149 starter-price footnote is now a full market-structure story: the cash-pay market is bifurcating, and $149 is the marginal clearing price for an oral GLP-1 trial start.
"Wegovy's cash price has dropped 75 percent since 2021 as drugmakers compete directly for patients"
— The Daily Economy
The Medicare GLP-1 Bridge — $50 monthly copays for eligible Part D seniors, live since July 1 — has reached ~700,000 seniors, and Ricks says Lilly is capturing "7 out of 10" Bridge patients (Fierce Pharma tracker). With fewer than one in five large employers covering GLP-1s for obesity and half of Wegovy/Zepbound sales now direct exchanges with cash payers, the U.S. market is splitting into three channels: a shrinking commercial-formulary channel, a fast-growing $50-copay Medicare channel, and a dominant cash/DTC channel where Lilly's $149 starter pricing is the weapon (The Daily Economy).
What to watch: Whether Novo closes the Bridge enrollment gap — the new thread tracking Bridge dynamics is the right place to steer that question.
Viking Round-Trips; the Market Still Pays for Mechanism (Escalated)
Last cycle's bullish maintenance readout got the full market treatment: spike, then dilution.
"Those taking the medicine every other week maintained up to 97% of their weight loss three months after switching to this new dosing schedule, and patients taking it monthly maintained up to 90%."
— The Motley Fool
VKTX surged 36% on the readout, then closed a $575.0M stock-and-convertible offering on September 28 — necessary given $125.8M cash against $125.2M of quarterly burn as of June 30 — leaving the stock at $29.94 by Oct 2, down 27.2% over three months (VKTX market view). The new contrast is Structure Therapeutics: GPCR is down 41.6% in a month (RSI 16) with no single confirmed catalyst — an EPS miss, a year-long grind, and compression of the oral GLP-1 premium thesis as Foundayo scales at $149. Differentiated mechanism gets rewarded; undifferentiated oral exposure doesn't.
What to watch: The oral VK2735 Phase 3 initiation by year-end (carried over from last cycle), plus the Q4 SWITCH readouts that could explain GPCR's slide.
Big Food's Headwind Gets Household-Level Proof (Escalated)
Last cycle's brand-value estimates ($73B flagged, Lay's $6.8B at risk) now have measured household behavior underneath them.
"grocery spending fell about 5% within six months of a household adopting a GLP-1, and that increased to more than 8% for higher-income households"
— Cornell study via Barchart
Confectionery, chocolate, and savory snacks are the flagged risk categories, with PepsiCo called the weakest of the big three — North American snack volumes and pricing both under pressure, plus an activist investor — while Mondelez has held up best on emerging-market exposure (Barchart). The adoption math: JPMorgan estimates ~10 million Americans were on GLP-1s in 2025, reaching 25–30 million by 2030, and Morgan Stanley projects $190B in global diabetes-plus-obesity drug sales by 2035 versus ~$79B in 2025. The medtech angle sharpened: Lilly's retatrutide hit 28.3% average weight loss at 80 weeks — against the 25–35% typical of bariatric surgery.
What to watch: Unchanged from last cycle — Q3/Q4 food-major earnings calls beginning to quantify GLP-1 commentary the way bariatric-surgery volumes already have.
What surprised us
- [NEW] Novo's switch study is a better defense than its share claims. The 194-patient Ro study — patients losing 4.1% more weight after switching off injectables, obesity prevalence falling from 87.1% to 65.5% — is the first data that makes the Wegovy pill's convenience pitch empirical rather than aspirational (Reuters via U.S. News). It hasn't moved the stock, but it's the argument Novo will lead with.
- [NEW] Lilly is fighting with cross-trial math now. Pooling ACHIEVE-3 against Novo's PIONEER PLUS and SURMOUNT-1 against STEP UP to claim 1.5–4.5% greater weight loss is commercially useful and scientifically soft — BMO's "indirect but encouraging" framing is generous (BioSpace). Expect Novo to return the favor.
- [NEW] China is now exporting molecules, not just patients. Novo licensed Hengrui's HRS-1596 pre-Phase 1 for $300M upfront (up to $2.6B), and Pfizer paid up to $495M for China rights to Sciwind's ecnoglutide (Barchart). The licensing geography has flipped.
Open threads
Carried over / absorbed into the body:
- CagriSema FDA decision (Q4 2026) — no longer a standalone thread; absorbed into the Novo discount section as the nearest re-rating catalyst.
- Q3 2026 earnings round — absorbed into the Novo section's "what to watch" (early November, first read on the Wegovy pill stall).
Dropped without resolution:
- NAION MDL-3163 milestones — the litigation thread vanished along with the section covering it. If you were tracking bellwether selections or FDA label action, nothing in this cycle updates it.
New this cycle: